English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Microdosing Psychedelics at Work: What the Science Actually Says
A few years back, the CEO of a marketing startup got fired for taking a tab of LSD before a company meeting. Not a recreational dose — a sliver, what people in certain circles call a microdose. He said it would sharpen his focus. The board said it violated company policy. The internet, predictably, lost its mind for about forty-eight hours and then moved on. But the question underneath that story hasn't gone anywhere. Does microdosing psychedelics actually do what people claim it does? Is it a legitimate cognitive tool, a placebo with great PR, or just an expensive way to get on the wrong side of the law? If you're reading this, you've probably wondered. Maybe a friend swears by it. Maybe you've read a profile of a founder who credits LSD with their breakthrough. Maybe you're curious whether the same compounds being studied for depression and addiction might quietly help you, too. Here's what the research actually shows, what experienced clinicians say, and why the relationship between microdosing and the deeper work of plant medicine is more interesting — and more honest — than the workplace-hack version of the story. A microdose is a sub-perceptual dose. That's the technical definition. You take roughly a tenth of what a recreational user would take — somewhere around 10 to 20 micrograms of LSD, or 0.1 to 0.3 grams of dried psilocybin mushrooms — at intervals over weeks or months. The idea is that you feel almost nothing. No visuals, no ego dissolution, no cosmic download. Just a faint shimmer underneath your normal day. People who microdose report better mood, more creative thinking, sharper focus, an easier time meditating, and reduced anxiety. Those are the claims. The protocol most often cited — one day on, two days off — comes from psychologist James Fadiman, who's been writing about this since the 1960s. He's the godfather of the whole movement, and he's also remarkably measured about what he thinks it does. What microdosing is not is a psychedelic experience. You don't journey on a microdose. You don't confront your shadow or meet ancestors or weep through twenty years of unprocessed grief. That's macrodose territory — heroic doses, as researchers call them — and it's a fundamentally different thing. Conflating the two is one of the more common mistakes people make when they start reading about this stuff. Short answer: not really. Not yet, anyway, and possibly not at all in the way enthusiasts hope. The most rigorous study to date, published a few years ago in eLife, ran a self-blinded trial where participants took either real microdoses or placebos. Both groups reported improvements in mood, energy, and cognition. The catch? The improvements were essentially identical. The active-dose group didn't outperform the placebo group in any meaningful way. The researchers' polite conclusion was that the reported benefits of microdosing appear to be largely placebo-driven. That's not nothing. Placebos are powerful. If taking a tiny dose of something exotic makes you believe you'll be sharper and calmer, you probably will be sharper and calmer for a while, because expectation shapes experience. But you can get the same effect from a daily ritual, a multivitamin, or — if we're being honest — a decent cup of coffee. Researchers at Johns Hopkins, who run the most established psychedelics program in the country, have been blunt: the strong evidence for psychedelics as a therapeutic tool lives almost entirely at the high-dose end. The benefits don't seem to scale down. If anything works at microdose levels, it's most likely a mild antidepressant effect from nudging the serotonin system — which is also exactly what SSRIs do, with fewer legal complications and decades more safety data. The tech industry's romance with microdosing isn't really about the pharmacology. It's about the story. Steve Jobs famously called taking LSD one of the most important experiences of his life. Founders trade Fadiman's protocol like a productivity hack. The narrative goes: smart, ambitious people gain an edge by treating their brains like an OS that can be patched and optimized. And look — the underlying impulse isn't crazy. Psychedelics genuinely do something to cognition. People who take real, meaningful doses in well-held settings often describe lasting shifts in perspective, creativity, and emotional flexibility. The mistake is assuming you can get those benefits in tenth-strength increments while still running a 10 a.m. stand-up. You can't, mostly. The actual transformative effects of psychedelics seem to require the full experience — the discomfort, the surrender, the eight hours where you cannot, under any circumstances, lead a meeting. That's not a bug. That's the point. The deep work happens precisely because the usual self is offline. This is the part of the conversation that gets glossed over in glowing founder profiles. LSD, psilocybin, and MDMA are Schedule I substances in the United States. Possessing them is a federal crime. Microdosing at work, the way the Iterable CEO learned, can also end your career fast — even in companies that consider themselves enlightened about substance use. Then there are the practical issues. When you're sourcing tabs or mushrooms from someone you met through a friend of a friend, dose accuracy is a fantasy. People aim for 15 micrograms of LSD and accidentally take 80. Suddenly the wall is breathing during a budget review. Researchers have heard versions of this story more times than they care to count. Some honest concerns to sit with if you're considering this: If you've gotten this far, you might be sensing the more interesting question underneath all this. People aren't microdosing because they want to optimize quarterly OKRs. Most of them are quietly hoping for something deeper — relief from depression, a way out of an addiction, a softening of trauma, a sense that there's more to life than the loop they've been running for fifteen years. That's the territory where psychedelics genuinely shine, and it's not microdose territory. Clinical trials with psilocybin for treatment-resistant depression have produced results that legitimately surprised the researchers. Ibogaine has helped people walk away from opioid dependency in ways nothing else has. Ayahuasca ceremonies, conducted in traditional contexts with experienced facilitators, have given people decades of stuck patterns to chew on in a single night. These are the master plants — substances that traditional cultures have worked with for generations, in settings designed to hold the weight of what they bring up. The honest framing is this: a microdose is a hack. A retreat is a reckoning. They're different tools for different jobs. If what you actually want is a slightly better Tuesday, drink a coffee and go for a walk. If what you want is to look honestly at why your Tuesdays feel the way they do — that's a different conversation, and it probably involves a real dose, a real container, and people who know what they're doing. The thing about psychedelic healing — the real thing, not the productivity version — is that it works in the opposite direction from optimization. It asks you to slow down, not speed up. It rewards surrender, not control. The Silicon Valley pitch of move-fast-and-break-things is almost exactly the wrong posture for the work. People who come out of a well-run retreat tend to describe months of integration afterward. Slow re-entry. Conversations with a therapist or guide. Changes that show up not as a sudden flash of insight but as a different relationship to their own habits over time. None of that fits in a microdose protocol. None of it shows up in a single ceremony, either — the integration is the medicine, in many ways. If you're weighing whether this path makes sense for you, take your time. Read accounts from people who've done it. Ask hard questions about lineage, safety screening, and what happens if something difficult comes up in ceremony. The good operators welcome those questions. The sketchy ones don't. For readers who want to explore this more seriously, a range of vetted ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. It's a quieter and more considered route than the workplace microdose — and, by most accounts of the people who've actually done both, a far more useful one.
Why Venture Capital Is Skeptical About Oregon's Legal Psilocybin Market
Oregon did something genuinely historic when it voted to create the first state-regulated psilocybin program in the country. For anyone interested in psychedelics, plant medicine, or the slow drift of mushrooms out of the underground and into licensed spaces, it was a moment worth marking. So you'd assume the venture capital crowd — the same people pouring tens of millions into psychedelic startups — would be lining up at the border with checkbooks open. They're not. Several of the most active investors in the psychedelics space have quietly made it clear they're skipping Oregon, at least for now. Their reasoning is worth understanding, because it tells you something useful about where this whole industry is heading — and what it might mean for the kind of retreat experience you can actually book in the years ahead. Measure 109 created a framework where adults can take psilocybin under the supervision of a licensed facilitator at a licensed service center. It's not medical. It's not recreational. It's a third thing — call it supported use — and it sits inside a single state while psilocybin remains a Schedule I substance at the federal level. That last detail is doing a lot of heavy lifting in this story. The companies preparing to operate in Oregon are mostly retreat centers, training programs for facilitators, and small clinic-style operations. Some are familiar names in the psychedelic retreat world — outfits that have spent years running ceremonies in places like the Netherlands or Jamaica and now want a foothold inside the United States. On paper, it looks like the beginning of a real market. Talk to people running psychedelic-focused venture funds and a few specific objections come up again and again. None of them are about whether psilocybin works. They're about whether a business built around it can make money under the rules as written. The first issue is taxes. Because psilocybin is federally illegal, businesses handling it get hit by the same IRS provision — Section 280E — that has been making life miserable for cannabis operators for years. In plain English: you can't deduct normal business expenses like rent, payroll, or marketing the way an ordinary company can. Your effective tax rate balloons. Margins that already look thin get sliced even thinner. The second issue is the math of a single session. A ketamine clinic — currently the closest legal comparison in the US — can move a patient through treatment in roughly an hour or two. A psilocybin session runs significantly longer; six hours is a reasonable baseline once you add preparation and the come-down. That's one room, one facilitator (sometimes two), one client, for most of a working day. Even at premium pricing, the unit economics get tight fast. The third issue is scale. Venture capital looks for businesses that can grow ten or a hundred times larger with an injection of cash. A retreat center on a 124-acre property in southern Oregon is a beautiful thing. It is not, in the VC sense, scalable. You can't ship it. You can't 100x it. You can open a second one, eventually, and that's about it. The money is mostly flowing somewhere else: toward biotech companies running clinical trials on psilocybin, MDMA, and related compounds, hoping to get them approved as prescription medicines through the FDA. If that approval comes — and several late-stage trials suggest it might, for conditions like treatment-resistant depression and PTSD — those companies suddenly have a federally legal product, insurance reimbursement, and a defensible patent position. That's a very different business than running ceremonies in a wooden lodge with a facilitator who sings to you for six hours. It's pharmaceutical psychedelics. It's also where most of the venture capital has gone for the past several years, and it explains a lot about the public conversation around psychedelic healing — what gets covered, what gets funded, what gets framed as legitimate. Here's where it gets interesting for the person actually researching whether to sit in a ceremony. The VC cold shoulder toward Oregon isn't necessarily bad news. In some ways it might be the best thing that could happen to the experience itself. When venture money flows in, it brings expectations. Growth targets. Standardized protocols. Pressure to move clients through faster. The retreat world has spent decades being shaped by tradition, by individual facilitators, by lineage, by the slow accumulation of practice. The places that resist quick scaling are often the ones doing the most careful work. That said, there are some practical things worth knowing if you're weighing Oregon as a destination versus going to an established ayahuasca or psilocybin retreat abroad: Most of this VC drama is centered on psilocybin specifically, because that's what Oregon legalized. But it sits inside a bigger conversation about plant medicine as a whole. Ayahuasca, San Pedro, iboga, peyote — what indigenous traditions often call master plants — operate in a legal and cultural space that's even more complicated than mushrooms in Oregon. They're not on the table for state-level legalization in the US anytime soon, and the established retreats for these medicines are almost entirely outside the country. For people seeking help with addiction, depression, or the kind of stuck patterns that talk therapy hasn't budged, the choice often comes down to: wait for a clinical pipeline that may or may not deliver a relevant treatment in five years, try the new Oregon model when it opens up, or travel to an established retreat tradition that has been doing this work for decades or centuries. None of these is automatically the right answer. They're different doors into different rooms. What's clear is that the underground-to-legal transition is messier than the headlines suggest. The investors backing away from Oregon aren't doing it because they think psychedelics don't work. They're doing it because they think the business model is hard. Those are different things, and confusing them leads to bad decisions on both ends — investors missing real opportunities, and seekers assuming that what gets the most funding must be the best path to healing. If you're somewhere in that 22-to-60 bracket of adults quietly looking into this for real reasons — addiction in the family, depression that won't lift, grief that's gone on too long — the most useful thing you can do is ignore the industry noise and ask basic questions of any program you're considering: You won't find these answers in a glossy brochure. You'll find them in long phone calls, honest references, and the willingness of a retreat to talk about hard cases instead of dream testimonials. The legal landscape will keep shifting. Oregon will figure out its market, or it won't. Colorado, which passed its own measure shortly after, will run its own experiment. Federal approval for psilocybin therapy could land within a few years. None of that changes the basic question for the person reading this: is plant medicine the right next step for you, and if so, with whom, where, and when? For readers who want to explore this further with a clearer view of the options, a curated range of ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Kambo Ceremony Explained: What Frog Medicine Actually Does to Your Body
The first time someone described a kambo ceremony to me, I thought they were pulling my leg. Frog secretion. Burned into the skin. Twenty minutes of vomiting. Then, supposedly, weeks of feeling sharper, lighter, more alive. I remember thinking — who signs up for this voluntarily? Turns out, a lot of people. And the more I sat with practitioners across the plant-medicine world, the more I realised kambo occupies a strange, fascinating corner of the psychedelic and master-plants conversation: not psychoactive, not gentle, but increasingly central to how people are approaching healing and recovery from chronic conditions. If you've stumbled across kambo while researching ayahuasca retreats or other plant medicines, you've probably noticed it shows up everywhere — usually as an optional add-on the morning before ceremony, or as a standalone session at detox-focused centres. Here's what's actually happening when someone takes it, what the experience is really like, and how to think about whether it belongs anywhere near your own healing path. Kambo is the dried secretion of the giant monkey frog, Phyllomedusa bicolor, native to the upper Amazon. Indigenous groups — particularly the Matsés, Katukina, Yawanawá, and Kaxinawá — have used it for generations, traditionally to sharpen hunters, clear what they call panema (a kind of stagnant, heavy energy), and strengthen the body before long treks through the forest. The frog is not killed. It's gently held against a frame, its legs spread, and a small amount of secretion is scraped from its back into a wooden stick where it dries. The frog is released back to the canopy. What ends up on that stick is a chemical cocktail — dozens of bioactive peptides, including dermorphin (a potent opioid analogue), phyllocaerulein, sauvagine, and several others that interact with the cardiovascular, immune, and central nervous systems in ways researchers are still mapping. The substance isn't psychedelic in the classical sense. You won't see visions or dissolve into the cosmos. What you will do is feel your body very, very intensely for about twenty minutes. To get kambo into the bloodstream, a practitioner burns small superficial points on the skin — usually the shoulder, forearm, or lower leg — using the tip of a smouldering vine or stick of incense. The top layer of skin is lifted away, and small dots of the rehydrated secretion are placed onto these openings. From there, it bypasses the digestive system entirely and enters the lymphatic system within seconds. Most ceremonies follow a recognisable arc. You'll be asked to fast for eight to twelve hours beforehand, then to drink one and a half to two litres of water in the half hour before application. This isn't optional. The water is what your body will use to flush during the purge, and skimping on it makes the experience genuinely unpleasant in ways it doesn't need to be. Many facilitators open with breathwork or a short meditation, sometimes followed by rapé — a fine tobacco-and-ash snuff blown into each nostril through a wooden pipe. Rapé hits hard and fast. It clears the sinuses, drops you abruptly out of your thinking mind, and sets a kind of ceremonial seriousness over the room. Then the burn points go on (less painful than it sounds — closer to a cigarette burn that fades within an hour), and the kambo is applied. The onset is shockingly quick. Within thirty seconds, your face flushes and your heart rate climbs. Within a minute or two, a heavy, dense pressure builds in your chest and head — practitioners call this the "frog punch." Your body temperature spikes. Your face may swell slightly. Then the purging starts, usually into a bucket placed within arm's reach. It's not pretty. It's also not as terrible as it sounds in the abstract — the body is doing exactly what it's meant to do, and most people describe a strange, almost relieved clarity once the wave breaks. Twenty to thirty minutes later, it's essentially over. The points are wiped, you're given water or coconut water, and you rest. Most people sleep deeply that night. The day after, many report a quality of stillness and energy that's hard to describe — not high, exactly, but cleared out. Practitioners and traditional sources attribute a long list of benefits to kambo: relief from chronic pain, improvements in autoimmune symptoms, reductions in anxiety and depression, help with addiction and cravings, antimicrobial effects against parasites and candida, and improvements in lymphatic and immune function. Some of this has plausible mechanism behind it. Dermorphin and related peptides are roughly forty times more potent than morphine as analgesics. Some peptides do show antimicrobial activity in lab settings. Sauvagine appears to act on stress-response pathways. That said, I want to be straight with you: the peer-reviewed clinical evidence in humans is thin. Most of what we have comes from biochemistry papers describing the peptides themselves, anecdotal reports from practitioners, and a handful of small studies. Kambo also carries real risks. It significantly elevates heart rate and blood pressure. It causes electrolyte shifts. There have been documented deaths, usually linked to over-hydration, undisclosed cardiac conditions, or untrained practitioners pushing too many points. Kambo is contraindicated for: A competent facilitator will screen you for all of this before agreeing to work with you. If someone is willing to apply kambo without asking detailed health questions, walk away. That's the first and clearest red flag. Among the master plants, kambo occupies an unusual place. It isn't a teacher plant in the way ayahuasca or San Pedro are — it doesn't speak, doesn't show visions, doesn't deliver narrative insight. What it offers is something more like a hard reset of the physical body. People who work seriously with ayahuasca often use kambo in the days before a ceremony, the idea being that a cleaner body makes for a clearer journey. Others use it on its own, returning every few months for what they describe as maintenance. For people in addiction recovery, kambo has drawn interest because of how it seems to affect cravings and the body's stress regulation. It's worth saying carefully: kambo is not a cure for addiction. But as part of a broader recovery plan that might include ibogaine, ayahuasca, therapy, and integration work, some people find it useful for breaking through the somatic component of addiction — the body's stored tension and dysregulation that talk therapy alone can't always reach. If you're weighing kambo as part of a wider healing arc, think of it as a tool, not a transformation. The week after a session is often a window where deeper work — therapy, journaling, integration with a trusted guide — lands more easily. Without that follow-through, you may feel briefly cleansed and then return to the same patterns within a month. This is the part that matters more than anything else above. A good kambo practitioner has spent years apprenticed under traditional or rigorously trained lineage holders, screens carefully, keeps their points conservative, has emergency protocols, and never pressures a participant to take more. Questions worth asking before you book: If the answers are vague, evasive, or skip past the safety questions to focus on benefits, keep looking. The plant-medicine and psychedelic recovery space attracts wonderful, dedicated practitioners — and a smaller number of opportunists who learned the basics from a weekend workshop. The cost of choosing badly here isn't a disappointing experience. It can be a hospital visit. Honestly? For some people, yes. For others, no. Kambo isn't gentle and it isn't subtle, and the discomfort is real for the duration. But for people who feel genuinely stuck — chronic inflammation, lingering depression, the kind of low-grade physical heaviness that no amount of green juice has shifted — a properly held session can do something that's hard to articulate until you've felt it. A friend of mine described her first ceremony as "like someone opened a window in a room I didn't know was stuffy." That's about as accurate as I've heard it put. The honest take is that kambo rewards preparation. Show up well-rested, well-hydrated in the days leading up, with realistic expectations and a facilitator you trust. Don't combine it with other psychedelics or plant medicines on the same day unless your practitioner explicitly recommends it. Give yourself a quiet day afterward. Pay attention to what shifts in the following weeks — that's where the real information is. For readers wanting to explore this further alongside other plant-medicine work, a range of kambo and broader psychedelic retreats can be browsed on our marketplace here. Whatever path you take, take it slowly. The medicines that work the deepest tend to reward people who treat them — and themselves — with patience.
Zen, Psychedelics, and Shamanic Wisdom: Three Paths Into Nature Mysticism
Somewhere around the third hour of a ceremony in the Peruvian jungle, I stopped being able to tell where my skin ended and the night began. The frogs were inside my chest. The river was running through my spine. It wasn't a metaphor — it was the most literal thing I'd ever felt. Years later, sitting a silent zazen retreat in a drafty zendo in upstate New York, something quieter but unmistakably related happened on a Tuesday morning at 5:42 a.m. No drama. Just the sudden, almost embarrassing recognition that I had been a single weather pattern inside a much larger one the whole time. What I want to talk about here is the strange overlap between three traditions that, on paper, have nothing to do with each other: Zen Buddhism, psychedelic mysticism — including ayahuasca and the broader family of master plants — and indigenous shamanism. They use wildly different methods. They speak different languages. And yet people who go deep into any of them keep reporting back the same odd piece of news: the gap between you and the world is not what you think it is. If you're researching a retreat — psychedelic, contemplative, or somewhere in between — this overlap is worth understanding. Because the experience these paths are pointing toward is also, increasingly, what people are leaning on for healing trauma, loosening addiction, and finding their way out of stuck patterns. It's hard to talk about nature mysticism in 2026 without acknowledging the obvious. The climate is breaking down. Species are vanishing at rates no human civilization has witnessed. The reasonable, technocratic responses — policies, carbon markets, electric cars — are necessary and nowhere near sufficient. Plenty of thoughtful people have started saying the quiet part out loud: the crisis is downstream of a worldview. We treat the living world as inventory because we experience ourselves as separate from it. This is where the contemplative and psychedelic traditions get genuinely interesting. They don't argue you out of the separation. They dissolve it, at least temporarily, in a way you can feel in your body. And once you've felt it — really felt it, not read about it — the math of "how much rainforest is acceptable to lose" starts to feel like asking how much of your own lung you'd like surgically removed. That shift in felt sense is what philosophers call interbeing. It's also, I'd argue, the most underrated reason people leave a well-run retreat changed. Zen gets misrepresented in two opposite directions in the West. One camp paints it as gentle mindfulness with a side of incense. The other treats it like an elite cognitive sport for monks with knees of steel. Both miss the point. The classical project of Zen is to wear out your conceptual machinery until something underneath it reveals itself. Sōtō practitioners do this through shikantaza — "just sitting," which sounds simple and is genuinely brutal. Rinzai practitioners do it through koan work, those famous riddles designed to short-circuit logical reasoning. The aim in both cases is kensho: a moment of seeing your own nature, which turns out to be inseparable from everything else's. Practitioners describe it in remarkably consistent terms. The sense of being a discrete self inside a skull, looking out at a world, just… stops. What's left is a kind of seamless field where the cedar tree, the kettle, the breath, and the listener are all variations of the same happening. Not metaphorically. Phenomenologically. Here's an honest caveat from someone who's spent time in both worlds: kensho doesn't automatically make you a good person, an environmentalist, or a stable human. Philosopher Graham Parkes made this point decades ago and it still holds — having a mystical experience of oneness doesn't, by itself, generate ethics. You can taste interbeing on Saturday and drive a hostile, oblivious commute on Monday. The insight needs scaffolding: a community, a teacher, ongoing practice, real-world ethical engagement. Without that, even profound experiences fade into dinner-party anecdotes. This is one of the most important things to internalize before any retreat, psychedelic or otherwise: the experience is the door, not the house. Psychedelic mysticism takes a faster, rougher road to similar territory. Where Zen patiently sands down the ego over years, compounds like psilocybin, mescaline, and especially ayahuasca tend to take a sledgehammer to it in a single night. Whether that's a feature or a bug depends entirely on the setting, the preparation, and the people holding space. Ayahuasca in particular is striking because the tradition behind it never separated the medicine from ecology in the first place. The Shipibo, the Shuar, the Asháninka — these cultures don't talk about "plant medicine" as a category distinct from the forest. The vine, the chacruna leaf, the songs, the diet, the river: it's all one practice. When Westerners show up at an ayahuasca retreat and report, with great surprise, that the plants seemed to be speaking to them, the maestros generally smile politely. Yes. That's how it works. What's compelling about the recent wave of clinical research is that it backs up, in cautious institutional language, what indigenous practitioners have said for generations. Psychedelic experiences reliably produce what researchers call "mystical-type" states — and the depth of those states predicts the durability of therapeutic outcomes for depression, PTSD, and substance dependence. The more dissolved your sense of separation gets, the more your nervous system seems to reorganize around something healthier. If you're weighing a psychedelic retreat for reasons that include depression, trauma, or addiction — and statistically, many readers are — there are a few things worth knowing that the glossier websites don't emphasize: The word "shamanism" gets thrown around loosely, often by people selling drum journeys in Topanga. The traditions it points to, however, are ancient, specific, and deeply local. A Q'ero paqo in the Andes is not interchangeable with a Bwiti nganga in Gabon. What they share isn't a technique — it's an underlying assumption that the natural world is densely populated with intelligences, and that human flourishing depends on staying in right relationship with them. This is animism, and it's been condescended to by Western thought for about four hundred years. It's also, awkwardly, the worldview that produces the most ecologically intact regions left on the planet. Indigenous-managed lands hold roughly 80% of remaining biodiversity. That's not coincidence. That's what happens when the river is treated as a relative rather than a resource. What shamanic practice offers — whether through ayahuasca, San Pedro, iboga, kambo, or methods involving no substance at all — is a structured way to re-enter that relational worldview. You're not just having an experience. You're being formally introduced to something that was always there. Strip away the surface differences and the same handful of things keep showing up across Zen, psychedelics, and shamanism: This is why I keep telling friends who are eyeing an ayahuasca retreat or a silent meditation intensive that the question isn't really "which one is right." It's "which one will I actually keep doing afterward." The path that fits your temperament, your obligations, and your capacity for follow-through is the one that will produce the change you're looking for. Most of the people I've watched genuinely heal — from addiction, from grief, from the kind of depression that medication couldn't reach — did it through some combination of these traditions, held by competent people, over a meaningful stretch of time. Not one weekend. Not one substance. A real arc. If you're considering plant medicine as part of that arc, take the preparation seriously. Find a center with experienced facilitators, medical screening, a clear lineage, and post-retreat integration support. Talk to alumni. Ask about safety incidents — every honest center has had at least one, and how they handled it tells you everything. For readers who want to take this further, a curated range of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. The forest, the cushion, the cup of bitter brew — they're all pointing at the same uncomfortable, liberating fact. You were never separate. The work, once you've seen that, is learning to live like it's true.
Cacao Ceremony Guide: What Happens When Chocolate Becomes Plant Medicine
The first time someone described a cacao ceremony to me, I rolled my eyes a little. Chocolate as medicine? It sounded like the kind of thing you’d find sandwiched between a sound bath and a crystal-charging workshop at a wellness festival. Then I sat in one. And while ritual cacao isn’t in the same weight class as ayahuasca or psilocybin — let’s be honest about that up front — it’s a real practice with a real lineage, and it’s become one of the most common entry points for people quietly curious about plant medicine but not ready to drink the brew. If you’re researching ayahuasca, ibogaine, or psychedelic retreats and you keep seeing cacao circles pop up on the same retreat schedules, here’s what’s actually going on, and whether it’s worth your time. Ritual cacao isn’t the cocoa powder in your pantry, and it isn’t a chocolate bar with extra cacao percentage on the label. It’s pure, minimally processed cacao paste — usually from Guatemala, Peru, or Ecuador — prepared in a ceremonial dose of roughly 30 to 45 grams. That’s several times what you’d get in a strong hot chocolate. The active compound everyone talks about is theobromine, a mild stimulant in the same family as caffeine but slower and gentler in the body. It also contains a small cocktail of mood-active compounds: phenylethylamine (the so-called “love molecule”), small amounts of anandamide, magnesium in serious quantities, and a handful of MAO-adjacent compounds that may extend the effects of those neurotransmitters. None of this gets you high in any classical sense. You don’t see visuals. You don’t lose your grip on reality. What you do get, in most people’s reports, is a soft warmth in the chest, a quieting of mental chatter, and a noticeable opening to your own emotions and to the people around you. Indigenous Mesoamerican cultures — Mayan, Aztec, Olmec — used cacao ceremonially for thousands of years before it became a commodity. The modern cacao ceremony, the one you’ll find in Berlin lofts and Tulum jungles, is a contemporary fusion: it borrows from those traditions, layers in breathwork, sound, dance, and intention-setting, and serves it to a Western audience hungry for connection. You arrive, you sit in a circle, someone brews a thick, slightly bitter dark drink and serves it in a small cup. There’s usually an invocation — some facilitators are deeply respectful of the Mayan roots, others go full new-age, your mileage will vary. You set an intention. You drink slowly. For the first twenty minutes, you might wonder if anything is happening. Then, gradually, you notice your breath has deepened. Your shoulders have dropped a few centimetres. There’s a warmth somewhere behind the sternum. The facilitator usually moves the group into movement, breathwork, or guided meditation — sometimes ecstatic dance, sometimes stillness. The cacao doesn’t do anything dramatic to you. It just makes it slightly easier to feel what was already there. People often describe a quieting of the inner critic. The voice that narrates every social interaction, that keeps a running tab on how you’re being perceived — it gets quieter. Not silenced, just turned down. In that gap, you tend to notice things: tension you’ve been carrying, emotions you’ve been postponing, a sense of connection to the others in the room that doesn’t require small talk. The comedown is gentle. There’s no crash, no integration crisis. You sleep well. You might wake up the next morning feeling unusually soft toward your partner, your colleagues, strangers on the train. That after-glow tends to last a day or two before normal life reasserts itself. Here’s where I want to be careful. Cacao gets called a “plant medicine” in retreat marketing, and that’s technically true — it’s a plant, it has medicinal effects. But it sits at a very different point on the spectrum than the substances most people mean when they use that phrase. Ayahuasca will rearrange the furniture in your psyche. Ibogaine will run you through a thirty-six-hour confrontation with your past. Psilocybin can fundamentally shift how you relate to depression or addiction. Cacao won’t do any of that. What cacao can do is something more modest but genuinely useful: I’ve met people who showed up to a cacao circle out of curiosity and, six months later, found themselves on a plane to Peru. I’ve also met people for whom cacao was enough — they didn’t need anything stronger, and the practice gave them what they were looking for. Both outcomes are legitimate. Mostly, yes. But there are real contraindications and the facilitators of the better ceremonies will ask about them. The big ones: The other thing worth saying: cacao is non-addictive, non-toxic at ceremonial doses, and legal everywhere. You can’t overdose in any meaningful clinical sense. The risks are real but they’re manageable, and the people running ceremonies with any real training will screen for them. The cacao world has the same problem as the broader retreat world: a wide range of skill, depth, and integrity. Some facilitators have trained for years with Mayan elders. Others watched a YouTube video and bought a wholesale block of ceremonial cacao on the internet. Here’s what to look for: Avoid anyone selling cacao ceremonies as a cure for serious mental health conditions. Cacao is supportive, not curative. If a facilitator promises healing from depression, addiction, or trauma in a single sitting, walk away. One of the nice things about cacao is that it’s legal, available, and — once you know what you’re doing — possible to work with at home. A solo cacao practice can be simple. You brew a ceremonial dose, sit somewhere quiet, set an intention, and let yourself feel whatever shows up. Some people pair it with journaling, others with movement or breathwork. There’s no right way. What I’ve noticed in my own practice and in talking with people who’ve worked with cacao for years: it rewards consistency more than intensity. A weekly cup in a quiet hour does more than a dramatic ceremony twice a year. It becomes a check-in with yourself, a way to ask how you’re actually doing under the surface noise. For readers using cacao as a stepping stone toward deeper plant-medicine work — or as integration support afterward — a range of curated plant medicine and ceremony retreats can be browsed on our marketplace here. Cacao isn’t the medicine that’s going to rearrange your life. But it might be the one that quietly opens the door to whatever comes next. And sometimes, frankly, a quieter door is exactly what you need.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Before You Microdose Psychedelics: 5 Things Worth Knowing First
Microdosing has gone from fringe biohacker experiment to dinner-party small talk in roughly a decade. Tech workers do it. Painters do it. Increasingly, new mothers wrestling with postpartum depression are quietly doing it too. And somewhere in the middle of that crowd is probably you — curious, a little cautious, wondering whether tiny amounts of psilocybin or another psychedelic might actually take the edge off whatever you’re carrying. Before you order anything from a friend-of-a-friend or pack a bag for a retreat, slow down. Microdosing isn’t risk-free, and the research everyone cites in headlines is messier than the headlines suggest. Here’s what I’d want a thoughtful friend to tell me before I started — drawn from years of sitting in ceremony, talking to facilitators, and watching readers wade through this decision. A microdose is roughly a tenth of a recreational dose — usually somewhere between 0.05 and 0.25 grams of dried psilocybin mushrooms, or a comparable sub-perceptual amount of LSD. The whole point is that you don’t trip. You don’t see geometric patterns crawling up the walls. You go to work, fold laundry, answer emails. The effect, if there is one, is supposed to be subtle: a slightly brighter mood, a touch more presence, fewer of those 3 a.m. thought-spirals. That’s the pitch, anyway. The reality is that responses vary wildly. Some people swear by their Monday-Wednesday-Friday protocol. Others feel nothing for weeks and quietly wonder if they wasted their money. A few notice anxiety creep up instead of down. It’s less a miracle and more a tool — one that works for some people, in some seasons, and not for others. Psychedelics are in the middle of a serious scientific second act. Universities and biotech companies are running clinical trials for psilocybin-assisted therapy on depression, addiction, end-of-life anxiety, and PTSD. Some early results have been genuinely striking. A few studies on full-dose psilocybin for treatment-resistant depression have produced response rates that would make any pharmaceutical company sit up straight. But here’s the catch: microdosing specifically has weaker evidence than the headlines suggest. A lot of the data comes from self-report surveys, where people who chose to microdose tell researchers it helped. That’s prone to placebo effects and selection bias — people who try it and feel nothing tend not to fill out the follow-up survey. Placebo-controlled trials so far have shown that much of the benefit may be expectation-driven. That doesn’t mean microdosing does nothing. It means the picture is fuzzier than your wellness podcast probably let on. Read the actual papers if you can. Look at sample sizes. Notice whether the study was blinded. If your decision is going to lean on science, lean on it honestly. I know. You probably don’t want to bring this up with your GP. The conversation can be awkward, and depending on where you live, you might worry about legal blowback or judgment. But there are real medical reasons to have it anyway. Psychedelics interact with a longer list of medications than people realize. SSRIs and SNRIs — the most commonly prescribed antidepressants — can blunt psilocybin’s effects and, in rare cases, contribute to serotonin syndrome at higher doses. Lithium combined with classical psychedelics has been linked to seizures. MAOIs, tramadol, certain migraine medications, and some antipsychotics all complicate the picture. Cardiovascular conditions matter too, because psychedelics nudge blood pressure and heart rate. If your regular doctor isn’t the right person, look for a harm-reduction clinician or an integration therapist who works in this space. Several telehealth services now specialize in psychedelic preparation consultations. You don’t need permission. You need information. This part rarely makes it into the wellness blogs, but it matters. Most of the plant medicines now sold to Western consumers — ayahuasca, peyote, San Pedro, iboga, psilocybin mushrooms — come out of long Indigenous lineages where people protected this knowledge through colonization, criminalization, and outright theft. Buying a baggie from a guy at a music festival is one thing. Pretending it has no history is another. Ask the practical questions. Where was the substance grown or harvested? If it’s a synthetic compound, who manufactured it and to what purity standard? If it’s a traditional medicine, are the people who originally cultivated this practice receiving anything in return — economically, or through proper credit? Reputable retreat centers will be transparent about all of this. Sketchy ones won’t. That tells you something. Sourcing also has a sharp safety edge. Street-bought LSD has been adulterated with research chemicals for decades. Mushrooms can be misidentified — some look-alikes will land you in the ER. If you’re going to do this, do it with material whose origin you can vouch for. People assume support systems matter for full ceremonies — the all-night ayahuasca sit where you might cry, vomit, or rearrange your understanding of your childhood. Microdoses are smaller, so the assumption goes, the scaffolding can be smaller too. Not quite. Even sub-perceptual amounts can loosen something. Old memories surface unexpectedly during an ordinary Tuesday morning. Grief you thought you’d handled shows up at your desk. The dose is small but the territory it touches isn’t. Before you start a protocol, think through: Integration isn’t just a buzzword from psychedelic Twitter. It’s the difference between an interesting Tuesday and a meaningful shift. Whatever the medicine stirs up, you still have to live with it on the other side. This one I’ll add from my own observation, because it gets skipped almost everywhere. Microdosing works best as part of a larger effort, not as a substitute for one. The people I’ve watched benefit most were already in therapy, already moving their bodies, already trying — and the microdose was a small assist on a road they were walking anyway. The people who treated it as a hack to bypass the hard work tended to circle back disappointed within a few months. If you’re considering psychedelics because of addiction, severe depression, or trauma that hasn’t responded to anything else, a full-dose container — a properly held ceremony or a clinical setting — may actually be more appropriate than a microdose protocol. Master plants like ayahuasca and iboga have a long track record in addiction recovery precisely because of the depth of the encounter, not despite it. A microdose won’t do what a ceremony does. They’re different tools for different problems. Psychedelics in any form aren’t a shortcut. They’re a magnifying glass — they enlarge what’s already there, including the parts you didn’t plan to look at. Microdosing is a gentler version of that magnifier, but it’s still the same instrument. Used carefully, with medical input, good sourcing, real support, and honest self-questioning, it can be one useful ingredient in a larger recovery or growth process. Used carelessly, it’s just another wellness trend you’ll quietly abandon by autumn. For readers who feel pulled toward something deeper than a microdose — a held container, experienced facilitators, time away from ordinary life — a range of vetted psychedelic and plant-medicine retreats can be browsed on our marketplace here. Take your time. The medicine, in whatever form, will still be there when you’re actually ready.
Psilocybin for Depression: What the Johns Hopkins Research Actually Found
A decade ago, the idea that a compound from a mushroom could be a serious candidate for treating major depression sounded fringe. Today it’s the subject of clinical trials at major research universities, the focus of FDA breakthrough therapy designations, and the quiet reason a lot of people in their thirties and forties are quietly googling “psilocybin retreat” at one in the morning. If you’re one of them, you probably want to know what the research actually says — not the headlines, not the hype. So let’s walk through it. Psilocybin, the psychoactive compound in what most people call magic mushrooms, has been studied on and off since the 1950s. The modern wave of research started small — pilot studies at Johns Hopkins, NYU, Imperial College London — many of them initially funded by private donors and nonprofits because federal money for psychedelic science was, for a long time, almost nonexistent. That early seed-funding mattered. It’s the reason we now have published data instead of just anecdotes. The mechanism question is the one researchers find most interesting, and it’s where the science has moved fastest. Brain imaging studies suggest psilocybin temporarily loosens the rigid patterns of communication that characterize the depressed brain. In people stuck in depression, certain networks — particularly the default mode network, which is heavily involved in self-referential thinking and rumination — tend to become overactive and locked-in. Psilocybin seems to quiet those entrenched circuits and, at the same time, open up new lines of communication between regions of the brain that don’t normally talk much. Researchers sometimes describe this as the brain entering a more flexible state. One Imperial College study described it as a kind of temporary “reset” of the depressive pattern. The metaphor isn’t perfect — nothing about the brain is that tidy — but it captures something real about why a single high-dose experience can sometimes shift moods that have been stuck for years. This is also why integration matters so much. The neuroplasticity window appears to stay open for days or weeks after the experience itself. What you do during that window — therapy, journaling, time in nature, honest conversations — seems to shape whether the changes hold. The most cited results come out of Johns Hopkins, where Roland Griffiths and colleagues ran landmark studies on psilocybin for psychological distress in cancer patients. A single high dose, paired with psychological support before and after, produced rapid and substantial reductions in depression and anxiety. The effects weren’t just statistically significant — they lasted. Six-month follow-ups still showed meaningful improvement in a majority of participants. A subsequent published trial extended those findings to people with major depressive disorder who didn’t have a terminal diagnosis. Two doses of psilocybin, embedded in roughly eleven hours of supportive therapy, outperformed what most antidepressant trials show. NYU’s parallel work with cancer patients reached similar conclusions. So did the larger Phase 2 trial run by COMPASS Pathways on treatment-resistant depression, where a single 25-milligram dose produced rapid antidepressant effects that were still measurable weeks later. These aren’t huge trials by pharmaceutical standards — we’re still talking about hundreds, not tens of thousands, of participants — but the signal is consistent enough that the FDA has granted psilocybin breakthrough therapy status. What does that mean for someone weighing a retreat? It means the underlying evidence is more substantial than skeptics often realize, and more provisional than enthusiasts often admit. Both things are true at once. The honest answer is that the current standard of care doesn’t work as well as we like to pretend. SSRIs help a real portion of people — but a real portion also don’t respond, or respond partially, or get unwanted side effects (numbing, weight gain, sexual dysfunction, the long taper if you ever try to come off). For people with treatment-resistant depression, the options shrink fast. Ketamine clinics have filled some of that gap. Psilocybin, if and when it’s approved for clinical use, is likely to fill more. Several public figures have spoken openly about their own depression in connection with funding or advocating for psilocybin research. Tim Ferriss is probably the best-known, having put significant personal money into the Johns Hopkins program and openly discussed his own struggles with suicidal ideation in his twenties. He’s not a clinician, and he’d be the first to say so, but his disclosure mattered because it modeled a kind of honesty most successful people avoid. What people in this space tend to share, regardless of their backgrounds, is the experience of feeling stuck — in a thought pattern, a behavior loop, a self-image — and the experience of psilocybin briefly making that stuckness negotiable. People expecting a recreational high are usually surprised. A therapeutic-dose psilocybin session, the kind used in the clinical trials, is closer to a six-hour interior excavation than a party. Participants typically lie down, wear eyeshades, and listen to a carefully curated music playlist while two trained facilitators sit nearby. There’s very little talking. The work happens inside. Common reports include: Griffiths’ research found that around seventy percent of participants rated their psilocybin experience as one of the five most meaningful of their lives. That’s a striking number — striking enough that careful scientists keep using the word “unprecedented.” It’s also why anyone considering this work should take it seriously, not casually. Outside the United States, psilocybin retreats operate legally in several countries — the Netherlands (where psilocybin-containing truffles remain legal), Jamaica, and a few others. If you’re researching options, the quality varies enormously. Some are deeply careful operations with medical screening, trained facilitators, and structured integration. Others are weekend parties dressed up with ceremony language. Telling them apart is the real work. A short list of questions worth asking before you book: A reputable program will answer all of these without defensiveness. If a retreat dodges the medical questions, that’s your answer. Depression is also one of the areas where preparation and integration arguably matter more than the experience itself — the dose isn’t a cure, it’s a window. What you do in the weeks after determines whether anything changes. Psilocybin isn’t for everyone. People with personal or family histories of psychosis, schizophrenia, or bipolar I are generally screened out of clinical trials for good reason. Certain heart conditions raise risks. And there’s the question of legal status — in most of the United States, psilocybin remains a Schedule I substance, with limited exceptions in Oregon and Colorado and a few decriminalized cities. The legal landscape is shifting, but it hasn’t shifted everywhere. Even for the right candidate, the experience can be hard. Sitting with old grief, watching a long-buried memory surface, feeling the full weight of a depressive pattern you’ve been numbing for years — none of that is pleasant in the moment. The research participants who reported the most benefit weren’t the ones who had the easiest sessions. They were the ones who let the difficult parts happen and then did the integration work afterward. If you’re someone who has tried the standard tools and still feels stuck, and you’re drawn to this for genuine reasons rather than novelty, it might be worth exploring further. For readers who want to take this further, a range of carefully vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, do it slowly, ask the uncomfortable questions, and treat the choice with the seriousness depression deserves.
Oregon's Psilocybin Market: What the New Legal Landscape Means for Retreat-Seekers
Oregon did something nobody expected a state to do this decade: it built the first legal, regulated framework for psilocybin services in the United States. Not decriminalization. Not a research carve-out. An actual licensed system where adults can sit with a trained facilitator and take mushrooms. For anyone weighing a psychedelic retreat — whether to wrestle with addiction, depression, or the kind of long-running unease that nothing else has touched — this matters more than the headlines suggested. So what does it actually look like on the ground? And how does it stack up against flying to Peru for ayahuasca or to Costa Rica for a plant-medicine retreat? Let's get into it, because the differences are bigger than they appear. Measure 109 passed in November 2020. The regulatory rollout took two more years, and the first licensed service centers opened their doors in mid-2023. Since then, the program has matured into something that genuinely functions — facilitators get trained and licensed, service centers get inspected, mushrooms get tested in labs, and clients book sessions much the way you'd book any other appointment. Here's the part most people miss: this isn't a medical model. You don't need a diagnosis. You don't need a doctor's referral. You don't even need to be an Oregon resident. What you do need is an intake appointment with a licensed facilitator, a session at a licensed service center, and an integration conversation afterward. The whole thing is structured, but it sits outside the traditional healthcare system. A typical session lasts about six hours. You arrive, you take a measured dose of psilocybin produced by a licensed Oregon grower, and a facilitator sits with you for the duration. No therapy in the clinical sense — Oregon's law specifically avoids that framing — but support, presence, and a safe container. This is where the conversation gets honest. The sticker shock is real. A single session at most Oregon service centers runs between $1,500 and $3,500, sometimes higher. That covers the preparation meeting, the session itself, the psilocybin, and at least one integration conversation. Group sessions tend to be cheaper per person. Solo sessions with experienced facilitators sit at the top of the range. Why so much? A few reasons worth understanding before you judge it too harshly: By contrast, an all-inclusive week-long ayahuasca retreat in Peru typically runs $1,500 to $3,000 — and that includes lodging, food, multiple ceremonies, and integration support. The math gets interesting fast. One Oregon session can cost roughly what a full retreat costs elsewhere. I've spent time in both worlds, and they're not interchangeable. People sometimes treat psychedelics as a single category — they aren't. The substance, the setting, and the tradition all shape what happens. Ayahuasca is a brew with deep Amazonian roots, used ceremonially by Indigenous peoples for centuries. You drink it in the evening, usually in darkness, often with icaros (medicine songs) sung over you. The experience is long — four to six hours of intense visionary states, often physically demanding, sometimes including purging. A traditional retreat puts you in community for days or weeks, with a shaman or curandero holding the space. Psilocybin in Oregon's model strips all of that away. The setting is clinical-ish — comfortable, but recognizably Western. The facilitator may have spiritual training or may not; the law doesn't require it. There's no ceremonial framework unless the facilitator brings one. The experience is shorter, generally gentler on the body, and — crucially — fully legal. No border crossings, no questions about jurisdiction, no gray areas. Which is better? Wrong question. Better for what? The licensing system filters out the most obvious bad actors, but it doesn't guarantee a good experience. Facilitators vary wildly in background — some are former therapists, some come from underground guide work, some were yoga teachers six months ago. The license tells you they completed a state-approved training program. It doesn't tell you whether they're someone you want sitting with you while you cry, or laugh, or fall apart for an afternoon. Things worth asking before you book: A good facilitator will answer these clearly and without defensiveness. If you get vague mystical hand-waving, keep looking. For years, the practical advice to anyone seriously interested in psychedelic healing was: travel. Go where it's legal, sit with reputable people, come home and integrate quietly. That advice still holds for ayahuasca, ibogaine, and most other plant medicines. But Oregon — and now Colorado, which passed a similar measure and is rolling out its own framework — has changed the equation for psilocybin specifically. Legal access removes a layer of stress that underground sessions can't escape. You're not worrying about a knock at the door. You're not asking a friend of a friend for a connection. You're not improvising aftercare alone in your apartment. That matters more than it sounds, especially for people whose stuck patterns include anxiety, hypervigilance, or histories of running from authority. It also professionalizes the field, for better and worse. Better: standards, accountability, basic safety screening. Worse: rising prices, a slow drift toward sanitized experiences, and the risk that the deep, weird, transformative quality of the medicine gets smoothed into something more palatable to wellness consumers. That depends on what you're after. If you're curious, financially comfortable, and want a legal, well-held introduction to psilocybin, Oregon is a reasonable starting point. If you're working with serious mental health concerns, the cost-per-session math may push you toward a traditional retreat where you get multiple ceremonies, community, and a longer container for less money. If you're drawn to the ceremonial dimension — the songs, the lineage, the sense of something older than yourself in the room — Oregon's clinical-leaning model may leave you feeling something is missing. None of these is the wrong choice. They're different doors into a similar room. The work that happens after — the integration, the slow re-patterning of how you live — is where the real outcomes get decided, regardless of which door you walked through. For readers who want to explore the broader options, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whichever path you choose, take it seriously, take it slowly, and bring the same honesty to the preparation that you'd want from the people sitting with you.
Ibogaine and Traumatic Brain Injury: What the Stanford Veterans Study Actually Found
Something unusual happened in a Stanford-led study published in Nature Medicine. Thirty Special Operations veterans — men carrying years of blast exposure, traumatic brain injuries, PTSD, depression, and in some cases active suicidal thoughts — flew to a clinic outside the United States, took a single dose of ibogaine paired with intravenous magnesium, and came back measurably different. Not slightly better. Not statistically nudged. Different in a way that the researchers described using effect sizes most psychiatric drugs never come within shouting distance of. If you've been quietly researching ibogaine for yourself or for someone you love — maybe a brother who came home from deployment and never really came home, maybe your own stuck pattern of addiction or depression — this study is worth understanding properly. Not the headline version. The actual one. Because ibogaine is powerful, it's serious, and the conversation around it has been a mess of hype and fear for decades. Let's slow down and look at what the Stanford team did, what they found, and what it means for anyone considering a psychedelic retreat involving this particular plant medicine. Ibogaine comes from the root bark of Tabernanthe iboga, a shrub native to Central Africa, where it's been used for generations in Bwiti spiritual ceremonies. In Western medicine, it's been studied mostly as a treatment for addiction — specifically opioid use disorder, where people have reported interrupted withdrawal and long stretches of sobriety after a single session. Pharmacologically, ibogaine is strange even by psychedelic standards. It touches NMDA, kappa and mu opioid, sigma, nicotinic, serotonin and dopamine systems, and it spikes neurotrophic factors like BDNF and GDNF that are linked to brain plasticity and repair. The experience itself isn't really a “trip” in the colorful, visionary sense people associate with ayahuasca or psilocybin. It's been called an oneirogen — a dream-inducer. Sessions last many hours, often well over a day, and participants describe long, lucid review states where memories, decisions, and unresolved material surface in a way that feels examined rather than chaotic. Think less fireworks, more long, brutally honest conversation with yourself. So why are veterans — particularly Special Operations veterans — seeking it out? Because the standard menu isn't working well enough. SSRIs, talk therapy, EMDR, exposure protocols: these help some people, but remission rates for combat-related PTSD hover stubbornly in the 20–40% range. Veterans account for roughly 20% of suicides in the U.S. while making up around 6.4% of the population. When the official toolbox keeps coming up short, people start looking elsewhere — and ibogaine has been quietly building a reputation in those circles for years. The protocol is called MISTIC — Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol. The magnesium part matters. Ibogaine's biggest historical safety concern is cardiac: it can prolong the Q–T interval, which in rare cases has led to fatal arrhythmias. Magnesium shortens the Q–T interval and has protective effects against drug-induced prolongation. Coadministering it isn't a cure-all, but the Stanford team built the protocol around the idea that supplementing magnesium during ibogaine dosing meaningfully reduces cardiac risk. Thirty male Special Operations veterans were enrolled. All had a history of TBI, most of it classified as mild and largely caused by repeated blast exposure. Half met criteria for major depressive disorder, nearly half for an anxiety disorder, and 23 of the 30 for PTSD. They received about 12 mg/kg of oral ibogaine alongside the magnesium protocol, with vital sign monitoring throughout. Treatment also included complementary therapies and integration support, which is worth noting — this wasn't ibogaine in isolation. The primary outcome was the World Health Organization Disability Assessment Schedule (WHODAS-2.0), a standard measure of how well someone functions in daily life. Secondary outcomes covered PTSD severity (CAPS-5), depression (MADRS), anxiety (HAM-A), suicidal ideation, and a battery of cognitive tests. Here's where the numbers start to look almost suspicious — until you read the methodology and realize the team measured carefully. And the safety picture? No unexpected or serious adverse events. No clinically meaningful Q–T prolongation. The most common side effects during dosing were headache, nausea, mild ataxia (wobbliness, basically) and intention tremor — all transient, all resolving within a day. Very. And the Stanford authors say so themselves. This was a prospective observational study, not a randomized controlled trial. There was no placebo arm. Participants knew they were getting ibogaine. They had self-selected into the treatment by traveling abroad to receive it, which means motivation and expectancy effects are baked into the results. The sample was 30 men, all from a specific Special Operations background, all with similar injury profiles. None of that invalidates the findings — but it does mean we can't extrapolate confidently to civilians, women, different TBI etiologies, or different psychiatric profiles. There's also the integration piece. MISTIC included complementary treatments and structured aftercare. Some unknown percentage of the benefit is likely attributable to the holding container around the ibogaine experience, not just the molecule itself. That's not a criticism — it's how serious psychedelic therapy works — but it matters for anyone imagining they could replicate this by simply dosing alone. What the study does do, convincingly, is signal that controlled trials are warranted and that the magnesium-coadministered protocol appears far safer than ibogaine's historical reputation suggests. That's a meaningful shift. Ibogaine remains a Schedule I substance in the United States, which is why this research had to be conducted on participants who traveled out of the country for treatment. Legal ibogaine clinics operate in Mexico, Costa Rica, Portugal, and a handful of other jurisdictions, with wildly varying levels of medical screening, cardiac monitoring, and aftercare. This variance is the single most important thing to understand before booking anything. If you're weighing a retreat, here's what to actually ask about — and what good answers look like: Ibogaine is not ayahuasca. It's not psilocybin. The experience is longer, more demanding on the body, and carries real cardiac considerations that the more commonly discussed plant medicines simply don't. It's also not for everyone — people with significant heart conditions, certain medications, or untreated substance dependencies that haven't been properly stabilized are poor candidates regardless of how badly they want relief. That said, what the Stanford work suggests — and what the broader field of psychedelic research keeps suggesting — is that some of these compounds, used carefully and within structured protocols, may do things conventional psychiatry has struggled to do for decades. Reduce PTSD. Lift treatment-resistant depression. Interrupt addiction. And, in this case, possibly help heal the cognitive and emotional consequences of brain injury that the medical system has largely written off as permanent. That's not a small claim, and it deserves the rigorous trials that are now being planned. For readers who want to keep exploring this thread responsibly, a curated selection of ibogaine and plant-medicine retreats can be browsed on our marketplace here. If you're reading this because someone you love is hurting, or because you are, the most useful thing this study offers isn't permission to rush. It's evidence that the door is wider than it looked, and that the people walking through it — with proper screening, proper monitoring, and proper integration — are sometimes finding what they came for.
Psychedelic Startups Worth Knowing About: A Plain-English Guide for Retreat-Seekers
Here's a question I get a lot from people sniffing around the edges of an ayahuasca or psilocybin retreat: Why is every other headline now about a psychedelic startup raising millions of dollars? Good question. Because if you're the kind of person seriously weighing whether plant medicine could help with depression, addiction, or that low hum of stuckness that no amount of journaling seems to fix, the answer matters. The money flowing into psychedelics is reshaping what's available, what's legal, and what kind of healing you can realistically access in the next few years. I'm going to walk you through what's actually happening in the startup world — without the jargon — and then bring it back to the only thing you probably care about: what this means for someone considering a retreat. Because here's the truth nobody in a pitch deck will tell you: the renaissance happening in labs and clinics is running parallel to, not replacing, the older tradition of ceremony, master plants, and the people who've been holding this work for generations. A few years ago, almost every psychedelic startup was a biotech company. They were trying to take psilocybin, MDMA, ibogaine, and various analogs through clinical trials, hoping to get them approved by regulators as medicines. That's still happening — and the trials are producing some genuinely jaw-dropping results, particularly for treatment-resistant depression and PTSD. But the landscape has gotten wider. Now there are companies building software to guide people through trip-like states without any substance at all. There are clinics offering legal, supervised ketamine therapy in dozens of US cities. There are AI platforms designing new psychedelic molecules from scratch. There are firms working on non-hallucinogenic versions of these compounds — yes, really — that aim to deliver the antidepressant punch without the eight-hour journey. And there are a handful of well-funded outfits trying to make synthetic mescaline, 5-MeO-DMT, and novel tryptamines into shelf-stable, prescribable medicine. Investors are betting this becomes a multi-hundred-billion-dollar industry within a decade. Whether you find that thrilling or a little nauseating probably depends on your relationship with the plants. Both reactions are reasonable. Roughly speaking, what's getting funded falls into four buckets. Knowing the difference helps you read the news without your eyes glazing over. Each of these affects you, the retreat-curious reader, in different ways. The drug developers will eventually make MDMA-assisted therapy and psilocybin therapy legal options in the US and Europe. The clinic networks already give you a legal entry point through ketamine. The tech companies are mostly noise, with the occasional gem. The discovery startups won't touch your life for years. Here's where I want to be honest with you. The biotech wave is exciting, but it isn't going to replace the experience of sitting in a maloca in the Peruvian Amazon, drinking ayahuasca brewed by someone whose grandmother brewed it, and confronting whatever it is you've been running from for twenty years. Those are different events. Both can heal. They're not the same thing. A clinical psilocybin trial gives you a precisely measured dose, a therapist in a clean room, eyeshades, and a curated playlist. A ceremony gives you icaros sung in Shipibo, a bucket, the sound of the jungle at three in the morning, and a worldview that treats the medicine as a teacher rather than a treatment. The clinical setting is safer in some ways and thinner in others. The ceremonial setting is richer in some ways and riskier in others. Anyone telling you one is strictly better than the other is selling something. What the startup boom does change for you: Because the industry is exploding, a lot of retreat centers have popped up that frankly shouldn't exist. Here's what I look for when someone asks me to vet a place — whether it's ayahuasca in the Amazon, psilocybin in Jamaica, or ibogaine for addiction in Mexico. The same skepticism applies to clinics, by the way. A ketamine clinic that doesn't include therapy alongside the infusion is mostly just selling you a dissociative experience. That can take the edge off depression for a few weeks. It probably won't change your life. I'll close with the thing I think gets lost in the investor-deck version of this story. The traditions around ayahuasca, peyote, San Pedro, iboga, and psilocybin mushrooms didn't show up because someone spotted a market. They've been refined over centuries, sometimes millennia, by people who understood these plants as relatives, not assets. The science is finally catching up to what those traditions already knew about consciousness, trauma, and addiction — which is a beautiful thing. But the catching-up is the point. The plants were here first. If you're researching a retreat right now, hold both truths at once. The clinical research is real and worth following. So is the older knowledge that says these are teachers, not treatments — and that what they teach you has to be lived out in your daily life or it slowly fades. The startups can build the delivery infrastructure. They can't build the courage it takes to actually sit down and drink the brew. For readers who want to take the next step, a range of vetted ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine, in whatever form you eventually meet it, will wait.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
